Fort Lee, New Jersey, USA, Feb. 3, 2015 (GLOBE NEWSWIRE) -- Herborium® Group, Inc.(OTC Pink: HBRM), www.Herborium.com, a Botanical Therapeutics® Company and provider of unique, all botanical medicines (Botanical Therapeutics®), announced today that its unique all herbal acne treatment, AcnEase®, will be featured in an editorial in the UK's most popular health focused publication, AT HOME MAGAZINE's Ask the Doctor with Dr. Christian Jessen on February 4th, 2015.
Herborium's Lasting Pleasure® and Lasting Power® formulas for women and men are also making their market debut in the same edition. The expected readership is over 1.2million.
The featured articles are followed by a massive social media publicity campaign targeting over a million unique visitors and over 1.1million page views per month led by Dr. Jessen, and will continue for 6 months.
Dr. Christian Jessen, Britain's favorite doctor, is the face of BAFTA award winning health focused television programs and the most popular medical public health speaker in the UK. His audience is affluent and educated, female consumers, with 75% of this audience commanding an income of more than £100,000 per year, making this an ideal target market for Herborium' s products.
In addition to mass distribution, Ask The Doctor is also distributed by specialty distributors such as British Air, Audi, Marriott and La Fitness, significantly increasing the audience and reach of the publication.
Acne is the most common skin condition in UK, with the average customer spending more than £150 a month for treatment.
Herborium's partnership with HUT Group, LLC, the UK's leading multi-website online retailer of Health and Beauty products, with a goal of £500,000.00 ($785,000.00) in sales within the coming 18-24 month period, provides additional support for AcnEase® growth in the UK and Europe.
The global market for sexual health formulas is over $8billion and the UK together with Germany, are the largest markets for these products in Europe.
"We are very excited about being chosen by At Home Magazine and Ask The Doctor with Dr. Christian Jessen to have our Botanical Therapeutics® featured in the most popular health media outlets in Great Britain. It is both recognition of our product and a tremendous marketing opportunity. This is a big step forward towards exponential growth in the UK and Europe for AcnEase®and our women's and men's sexual health products with the potential for millions in sales" commented Dr. Agnes P. Olszewski, CEO and Chairwoman of Herborium.
About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics® company that develops, license and markets proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium has secured a pipeline of botanical ingredients based products in the areas of dermatological needs, wellness and energy, prostate health, women's health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, diabetes, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce. For more information, please visit www.herborium.com, and www.acnease.com.
Safe Harbor Statement: This release contains forward-looking statements with respect to the results of operations and business of Sunrise Consulting Group, Inc., which involves risks and uncertainties. The Company's actual future results could materially differ from those discussed. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward looking statements be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995.